Stay updated on Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new site revision marker 'Revision: v3.4.2' was added and the previous 'Revision: v3.4.1' marker was removed. These are routine site maintenance/versioning updates and do not affect study content or availability; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdministrative notices were added: a government funding lapse notice with status guidance, and a software revision update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary display is now shown, and new metadata labels include Last Update Submitted that Met QC Criteria and Last Update Posted. The revision label has been updated to v3.4.0, and older labels such as Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), and No FEAR Act data have been removed or renamed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 replaces the previous v3.3.3 on the page. This is a minor update that does not affect study content or user-facing information; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations have been added by state (CA, DC, GA, MN, MO, NJ, NY, OH, TX) under a new Locations section; the HHS Vulnerability Disclosure link was removed, and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference1%

- Check91 days agoChange DetectedAdded a PubMed auto-fill publication notice and updated the revision from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page.